Stemcell Technologies Stemcell Technologies 25 Years

Live Webinar: Optimized Workflows for High-Efficiency Genome Editing in Stem and Primary Cell Types

Register Now
*Required
3D rendering of CRISPR-Cas9 and guide RNA interacting with DNA.
CRISPR-Cas genome editing in cell culture systems is a powerful technique for disease modeling and the development of cellular therapies. Compared to work with immortalized cell lines, genome editing of stem and primary cells presents unique challenges, including issues related to efficient delivery and expression of CRISPR machinery, clonogenicity, and cytotoxicity.

Join our live webinar with Dr. Ashley Watson, as she discusses how to optimize workflows for CRISPR-Cas9 genome editing in human pluripotent stem cells and primary T cells.


Ashley Watson, PhD
Scientist, STEMCELL Technologies
Live Webinar: Optimized Workflows for High-Efficiency Genome Editing in Stem and Primary Cell Types

Tuesday August 27, 2019 | 10 a.m. PST | 1 p.m. EST | 5 p.m. UTC

If you are unable to attend the live webinar, please register and a link will be sent to you with the recorded version.


Topics
  • Challenges associated with genome editing in stem and primary cell types
  • Approaches to support high-efficiency genome editing in human pluripotent stem cells and human primary T cells, including:
    • Optimized CRISPR-Cas9 genome editing methods
    • Pre- and post-editing culture considerations
Dr. Ashley Watson is a scientist at STEMCELL Technologies. Ashley received her PhD in Biochemistry and Developmental Biology from the University of Western Ontario in 2015, where she focused on the regulation of chromatin structure in neurodevelopment. She then completed postdoctoral training at the Massachusetts Institute of Technology, where she used CRISPR-Cas9 to generate novel two- and three-dimensional culture models of neurological disease from isogenic human induced pluripotent stem cells. At STEMCELL, Ashley is currently working to optimize genome editing in diverse cell types and oversees the genome editing and molecular tools product lines.